



**BHARATHIDASAN UNIVERSITY**

**Tiruchirappalli- 620024,**

**Tamil Nadu, India**

**Programme: M.Sc., Biomedical Science**

**Course Code: BM35C6**

**Course Title: Immunology**

**Unit-V**

**Overview of Autoimmunity and Transplantation**

**Dr. R. POORNIMA**

**Guest Faculty**

**Department of Biomedical Science**

## **Unit V:**

Overview of Autoimmunity and Transplantation - Autoimmune disease – Spectrum – organ specific (thyroid diseases, IDDM, pernicious anemia) and non-organ specific (Systemic sclerosis & SLE). Factors governing autoimmune diseases- genetic, hormonal, microbial and non-microbial. Regulatory mechanisms involved in autoimmune diseases- Tolerance – breakdown of tolerance (Modification of auto antigen, Cross-reactions with B cell epitopes, molecular mimicry of T cell epitopes. Transplants –auto, allo and Xeno- immunological complications of transplantation – graft rejection, GVHD –mechanisms – prevention of graft rejection- Immunosuppressant Drugs (Glucocorticoids, Calcineurin inhibitors, Antiproliferative/Antimetabolic agents) and antibodies as immunosuppressant

# **PRESENTATION: 2**

## **Regulatory Mechanisms in Autoimmune Diseases**

- Autoimmune diseases result from the immune system's failure to recognize self-antigens as non-threatening, leading to an attack on the body's own tissues.
- Central to this failure are the mechanisms of immune tolerance, which, when compromised, can lead to the breakdown of tolerance and subsequent autoimmunity.

# 1. Immune Tolerance

- **Immune tolerance** refers to the immune system's ability to distinguish between self and non-self, preventing an immune response against the body's own tissues. There are two main types of tolerance:

## A. Central Tolerance:

- **Location:** Thymus (for T cells) and bone marrow (for B cells).
- **Mechanism:** Developing lymphocytes that strongly recognize self-antigens undergo apoptosis (negative selection), or are rendered anergic (unresponsive).
- **Result:** Elimination or inactivation of self-reactive T and B cells before they mature and enter the periphery.

## **B. Peripheral Tolerance:**

- **Location:** Peripheral tissues.
- **Mechanism:**
  - **Anergy:** Self-reactive T and B cells that escape central tolerance become functionally inactivated when they encounter antigen without the necessary co-stimulatory signals.
  - **Regulatory T Cells (Tregs):** Specialized T cells (CD4<sup>+</sup> CD25<sup>+</sup> FoxP3<sup>+</sup>) suppress immune responses against self-antigens by secreting inhibitory cytokines (e.g., IL-10, TGF- $\beta$ ).
  - **Clonal Deletion:** Apoptosis of self-reactive cells upon repeated activation (activation-induced cell death).
  - **Immune Privilege:** Certain sites (e.g., eyes, brain) limit immune access to prevent damage.

## 2. Breakdown of Tolerance

- The breakdown of tolerance is a pivotal event in the development of autoimmune diseases. Several mechanisms can lead to this breakdown:

### A. Modification of Autoantigens:

- **Mechanism:** Post-translational modifications of self-proteins can create new epitopes that are not recognized as self by the immune system. These neo-epitopes can stimulate an autoimmune response.
- **Example:** Citrullination (conversion of arginine to citrulline) of proteins like vimentin in rheumatoid arthritis, creating novel antigens that trigger immune responses.

## **B. Cross-Reactions with B Cell Epitopes:**

- **Mechanism:**

B cells that recognize modified or cryptic epitopes on self-proteins may become activated by foreign antigens that share similar epitopes (molecular mimicry). These activated B cells can then produce autoantibodies against self-antigens.

- **Example:**

B cells recognizing modified DNA or RNA structures in systemic lupus erythematosus (SLE) produce autoantibodies that contribute to disease pathology.



## **C. Molecular Mimicry of T Cell Epitopes:**

- **Mechanism:**

Pathogens can express antigens that resemble self-antigens. When T cells recognize these pathogen-derived peptides, they may cross-react with similar self-peptides, initiating an autoimmune response.

- **Example:**

- **Rheumatic Fever:** Streptococcal M protein shares structural similarity with heart tissue, leading to cross-reactive T cell responses and cardiac damage.
- **Multiple Sclerosis:** Certain viral or bacterial proteins may mimic myelin basic protein, leading to T cell-mediated attack on myelin in the central nervous system.

## **D. Epitope Spreading:**

- **Mechanism:**

Initial immune response against a specific epitope of an autoantigen leads to the release of additional self-antigens, exposing new epitopes and broadening the immune attack.

- **Example:**

In SLE, initial attack on a specific nuclear antigen can spread to other nuclear components, expanding the autoimmune response.

## **E. Release of Sequestered Antigens:**

- **Mechanism:**

Self-antigens that are normally hidden from the immune system (e.g., inside cells or immune-privileged sites) can be released following tissue damage or infection, leading to an immune response.

- **Example:**

Trauma to the eye can release intraocular proteins, potentially leading to autoimmune uveitis.

## **F. Defects in Regulatory T Cells (Tregs):**

- **Mechanism:**

Tregs play a crucial role in maintaining tolerance. Deficiency or dysfunction of Tregs can lead to unrestrained immune responses against self-antigens.

- **Example:**

Mutations in the FoxP3 gene result in a lack of functional Tregs, causing immune dysregulation and polyendocrinopathy syndrome (IPEX).

## **G. Inflammatory Environment:**

- **Mechanism:**

Chronic inflammation can upregulate co-stimulatory molecules and cytokines, breaking tolerance and activating autoreactive T and B cells.

- **Example:**

Infections or tissue damage can create an inflammatory milieu that promotes autoimmunity, such as in Type 1 diabetes or rheumatoid arthritis.

### **3. Clinical Examples of Autoimmune Diseases and Breakdown Mechanisms**

#### **A. Type 1 Diabetes Mellitus (IDDM):**

- **Mechanism:**

Molecular mimicry and inflammatory destruction of pancreatic beta cells by CD8+ T cells.

- **Result:**

Loss of insulin production, hyperglycemia.

# Symptoms of Diabetes Type-1



Feeling very  
weak & hungry



Increase in  
frequency of  
urination



Blurred vision



Excessive thirst



Mood  
fluctuations



Nocturnal enuresis  
(bed-wetting) in children



Vaginal  
infections



Weight loss

## **B. Systemic Lupus Erythematosus (SLE):**

- **Mechanism:**


Defective clearance of apoptotic cells leads to the presentation of nuclear antigens, driving autoantibody production and immune complex formation.

- **Result:**

Multi-systemic inflammation and tissue damage.



# Systemic lupus erythematosus



## **C. Multiple Sclerosis (MS):**


- **Mechanism:**

Molecular mimicry and T cell-mediated destruction of myelin in the central nervous system.

- **Result:**

Demyelination, neuronal damage, and neurological deficits.

# Main symptoms of Multiple Sclerosis



## **D. Rheumatoid Arthritis (RA):**

- **Mechanism:**

Citrullination of proteins and formation of immune complexes in joints, leading to chronic inflammation and joint damage.

- **Result:**

Joint pain, swelling, and progressive disability.

**Rheumatoid  
Arthritis**  
(Late stage)


Boutonniere  
deformity  
of thumb

Ulnar deviation of  
metacarpophalangeal  
joints

Swan-neck deformity  
of fingers



# How Rheumatoid Arthritis Affects the Entire Body



## **4. Therapeutic Approaches Targeting Tolerance Restoration**

### **A. Immunosuppressive Drugs:**

- **Corticosteroids:** Reduce inflammation and immune responses.
- **Calcineurin Inhibitors:** Suppress T cell activation.

### **B. Biologic Therapies:**

- **TNF Inhibitors (e.g., Infliximab):** Reduce inflammation in diseases like RA.
- **B Cell Depletion (e.g., Rituximab):** Target B cells to reduce autoantibody production.

## **C. Tolerance Induction Strategies:**

- **Antigen-Specific Immunotherapy:** Desensitization to specific autoantigens.
- **Regulatory T Cell Therapies:** Enhancing Treg function to restore tolerance.

## **D. Targeting Inflammatory Pathways:**

- **Cytokine Inhibitors (e.g., IL-6 inhibitors):** Reduce inflammation by blocking pro-inflammatory cytokines.



# ACKNOWLEDGEMENT

- The presentation is being used for educational and non-commercial purposes.
- Thanks are due to all the original contributors and entities whose pictures were used to create this presentation.